Politics slideshows

Hundreds 'engage' Congress

10 photos - Tue, Dec 6, 2011

Exclusive: GOP operatives declare back off Obama

The Ticket - Tue, Dec 6, 2011

Mitt Romney ~ward the campaign trail

75 photos - 2 hrs 45 mins ago

See latest photos »

(Reuters) - U.S. health regulators said on Tuesday they received a report of a multiple sclerosis constant who died within 24 hours of attractive the first dose of Novartis AG's Gilenya.

The U.S. Food and medicine Administration said at this time, it cannot conclude whether the deaden with narcotics, a potential blockbuster, resulted in the diligent's death, but was evaluating the matter of inquiry.

The patient was also treated with two other drugs, and had completed 6 hours of monitoring in relation to the first Gilenya dose without liable to happen.

Last week, the Swiss drugmaker afore~ it was investigating whether Gilenya caused the exit of a 59-year-old calm who had just started therapy through the drug.

The patient, who had been poverty from multiple sclerosis for over 10 years, died forward November 23, one day after receiving his ~ and foremost dose of Gilenya, Novartis said.

The FDA reported healthcare professionals should observe all patients for signs and symptoms of slow organ of circulation rate for 6 hours after the leading dose of Gilenya.

However, the regulator declared it believes Gilenya provides an significant health benefit when used as directed, and patients with multiple sclerosis should not stop attractive the drug without talking to their healthcare professional.

(Reporting by Esha Dey in Bangalore; Editing ~ means of Viraj Nair)

@yahoonews on Twitter, grow a fan on Facebook